Complement-mediated tumour growth: implications for cancer nanotechnology and nanomedicines.

The recent unexpected observation that complement activation helps tumour growth and progression has an important bearing on the future development of cancer nanomedicines for site-specific tumour targeting as these entities are capable of triggering complement. These issues are discussed and suggestions are provided for future design and development of safer and effective cancer nanomedicines.

[1]  F M Muggia,et al.  Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Michael J Sailor,et al.  Biomimetic amplification of nanoparticle homing to tumors , 2007, Proceedings of the National Academy of Sciences.

[3]  M. Imai,et al.  Modulation of protective T cell immunity by complement inhibitor expression on tumor cells. , 2008, Cancer research.

[4]  S Moein Moghimi,et al.  Recent developments in polymeric nanoparticle engineering and their applications in experimental and clinical oncology. , 2006, Anti-cancer agents in medicinal chemistry.

[5]  Zhuang Liu,et al.  Drug delivery with carbon nanotubes for in vivo cancer treatment. , 2008, Cancer research.

[6]  H. Dai,et al.  Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover. , 2008, Molecular immunology.

[7]  S. Moghimi,et al.  Critical issues in site-specific targeting of solid tumours: the carrier, the tumour barriers and the bioavailable drug , 2008, Expert opinion on drug delivery.

[8]  S. Moghimi,et al.  PEGylation of microspheres generates a heterogeneous population of particles with differential surface characteristics and biological performance , 2002, FEBS letters.

[9]  B. Nilsson,et al.  Complement and coagulation: strangers or partners in crime? , 2007, Trends in immunology.

[10]  Dipak K. Sarker,et al.  Concentration dependent structural ordering of poloxamine 908 on polystyrene nanoparticles and their modulatory role on complement consumption. , 2006, Journal of nanoscience and nanotechnology.

[11]  Janos Szebeni,et al.  Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. , 2005, Toxicology.

[12]  G. Fleuren,et al.  Tumor-Specific Inhibition of Membrane-Bound Complement Regulatory Protein Crry with Bispecific Monoclonal Antibodies Prevents Tumor Outgrowth in a Rat Colorectal Cancer Lung Metastases Model , 2004, Cancer Research.

[13]  John D. Lambris,et al.  Modulation of the anti-tumor immune response by complement , 2008, Nature Immunology.

[14]  Stephen Tomlinson,et al.  Complement function in mAb-mediated cancer immunotherapy. , 2004, Trends in immunology.

[15]  Sai T Reddy,et al.  Exploiting lymphatic transport and complement activation in nanoparticle vaccines , 2007, Nature Biotechnology.

[16]  Janos Szebeni,et al.  Methylation of the phosphate oxygen moiety of phospholipid‐methoxy(polyethylene glycol) conjugate prevents PEGylated liposome‐mediated complement activation and anaphylatoxin production , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[17]  S M Moghimi,et al.  Long-circulating and target-specific nanoparticles: theory to practice. , 2001, Pharmacological reviews.

[18]  John D Lambris,et al.  Complement-targeted therapeutics , 2007, Nature Biotechnology.

[19]  J Szebeni,et al.  Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. , 2003, Progress in lipid research.

[20]  Poloxamer-188 revisited: a potentially valuable immune modulator. , 1996, Journal of the National Cancer Institute.